Developmental Hemostasis: Pro- and Anticoagulant Systems during Childhood

ABSTRACT

An understanding of developmental hemostasis is pivotal for optimal prevention, diagnosis, and treatment of hemostatic problems during childhood. The development of microassays in the early 1980s enabled researchers to delineate age-dependent features of the coagulation system and to establish reference ranges for healthy children of all age groups, from premature infants to adolescents. Based on the results from these studies, the hemostatic system in the young can be described as evolving, and yet functional, since healthy fetuses, infants, and children do not suffer hemorrhagic nor thromboembolic complications spontaneously or in the presence of minor challenges. Plasma concentrations of most pro- and anticoagulant proteins are decreased throughout childhood but provide an effective hemostatic balance on a lower level compared with adults. The current article describes the development of pro- and anticoagulant systems throughout childhood.

KEYWORDS

Coagulation - newborn - children - review

REFERENCES

• 1 Johnston M, Zipursky A. Microtechnology for the study of the blood coagulation system in newborn infants.  Can J Med Tech . 1980;  42 159-164
• 2 Andrew M, Paes B, Milner R. et al . Development of the human coagulation system in the full-term infant.  Blood . 1987;  70 165-172
• 3 Andrew M, Paes B, Milner R. et al . Development of the human coagulation system in the healthy premature infant.  Blood . 1988;  72 1651-1657
• 4 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood.  Blood . 1992;  80 1998-2005
• 5 Dahlbäck B. Blood coagulation.  Lancet . 2000;  355 1627-1632
• 6 Cade J F, Hirsh J, Martin M. Placental barrier to coagulation factors: its relevance to the coagulation defect at birth and to haemorrhage in the newborn.  Br Med J . 1969;  2 281-283
• 7 Gitlin D, Biasucci A. Development of gamma G, gamma A, gamma M, beta IC-beta IA, C 1 esterase inhibitor, ceruloplasmin, transferrin, hemopexin, haptoglobin, fibrinogen, plasminogen, alpha₁-antitrypsin, orosomucoid, beta-lipoprotein, alpha2-macroglobulin, and prealbumin in the human conceptus.  J Clin Invest . 1969;  48 1433-1446
• 8 Zilliacus H, Ottelin A M, Mattsson T. Blood clotting and fibrinolysis in human foetuses.  Biol Neonat . 1966;  10 108-112
• 9 Reverdiau-Moalic P, Delahousse B, Body G, Bardos P, Leroy J, Gruel Y. Evolution of blood coagulation activators and inhibitors in the healthy human fetus.  Blood . 1996;  88 900-906
• 10 Mazurier C, Daffos F, Forestier F. Electrophoretic and functional characteristics of the von Willebrand factor in human fetal plasma.  Br J Haematol . 1992;  81 263-270
• 11 Weinstein M J, Blanchard R, Moake J L, Vosburgh E, Moise K. Fetal and neonatal von Willebrand factor (vWF) is unusually large and similar to the vWF in patients with thrombotic thrombocytopenic purpura.  Br J Haematol . 1989;  72 68-72
• 12 Katz J A, Moake J L, McPherson P D. et al . Relationship between human development and disappearance of unusually large von Willebrand factor multimers from plasma.  Blood . 1989;  73 1851-1858
• 13 Thomas K B, Sutor A H, Altinkaya N, Grohmann A, Zehenter A, Leititis J U. von Willebrand factor-collagen binding activity is increased in newborns and infants.  Acta Paediatr . 1995;  84 697-699
• 14 Witt I, Muller H, Künzer W. Evidence for the existence of foetal fibrinogen.  Thromb Diath Haemorrhag . 1969;  22 101-109
• 15 Francis J L, Armstrong D J. Sialic acid and enzymatic desialation of cord blood fibrinogen.  Haemostasis . 1982;  11 223-228
• 16 Hassan H J, Leonardi A, Chelucci C. et al . Blood coagulation factors in human embryonic-fetal development: preferential expression of the FVII/tissue factor pathway.  Blood . 1990;  76 1158-1164
• 17 Karpatkin M, Blei F, Hurlet A, Greco A, Tang Z. Prothrombin expression in the adult and fetal rabbit liver.  Pediatr Res . 1991;  30 266-269
• 18 Karpatkin M, Lee M, Cohen L, McKinnell J, Nardi M. Synthesis of coagulation proteins in the fetus and neonate.  J Pediatr Hematol Oncol . 2000;  22 276-280
• 19 Holmberg L, Henriksson P, Ekelund H, Åstedt B. Coagulation in the human fetus. Comparison with term newborn infants.  J Pediatr . 1974;  85 860-864
• 20 Kisker C T, Robillard J E, Clarke W R. Development of blood coagulation-a fetal lamb model.  Pediatr Res . 1981;  15 1045-1050
• 21 Andrew M, O'Brodovich H, Mitchell L. Fetal lamb coagulation system during normal birth.  Am J Hematol . 1988;  28 116-118
• 22 McDonald M M, Hathaway W E, Reeve E B, Leonard B D. Biochemical and functional study of antithrombin III in newborn infants.  Thromb Haemost . 1982;  47 56-58
• 23 Schmidt B, Mitchell L, Ofosu F A, Andrew M. Alpha₂-macroglobulin is an important progressive inhibitor of thrombin in neonatal and infant plasma.  Thromb Haemost . 1989;  62 1074-1077
• 24 Cvirn G, Gallistl S, Muntean W. Effects of alpha2-macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma.  Thromb Res . 2001;  101 183-191
• 25 Andrew M, Mitchell L, Berry L. et al . An anticoagulant dermatan sulfate proteoglycan circulates in the pregnant woman and her fetus.  J Clin Invest . 1992;  89 321-326
• 26 Petäjä J, Fernandez J A, Fellman V, Griffin J H. Upregulation of the antithrombotic protein C pathway at birth.  Pediatr Hematol Oncol . 1998;  15 489-499
• 27 Suarez C R, Menendez C E, Walenga J M, Fareed J. Neonatal and maternal hemostasis: value of molecular markers in the assessment of hemostatic status.  Semin Thromb Hemost . 1984;  10 280-284
• 28 Yuen P M, Yin J A, Lao T T. Fibrinopeptide A levels in maternal and newborn plasma.  Eur J Obstet Gynecol Reprod Biol . 1989;  30 239-244
• 29 Greffe B S, Marlar R A, Manco-Johnson M J. Neonatal protein C: molecular composition and distribution in normal term infants.  Thromb Res . 1989;  56 91-98
• 30 Schwarz H P, Muntean W, Watzke H, Richter B, Griffin J H. Low total protein S antigen but high protein S activity due to decreased C4b-binding protein in neonates.  Blood . 1988;  71 562-565
• 31 Menashi S, Aurousseau M H, Gozin D. et al . High levels of circulating thrombomodulin in human foetuses and children.  Thromb Haemost . 1999;  81 906-909
• 32 Weissbach G, Harenberg J, Wendisch J, Pargac N, Thomas K. Tissue factor pathway inhibitor in infants and children.  Thromb Res . 1994;  73 441-446
• 33 Patel P, Weitz J, Brooker L A, Paes B, Mitchell L, Andrew M. Decreased thrombin activity of fibrin clots prepared in cord plasma compared with adult plasma.  Pediatr Res . 1996;  39 826-830
• 34 Schmidt B, Ofosu F A, Mitchell L, Brooker L A, Andrew M. Anticoagulant effects of heparin in neonatal plasma.  Pediatr Res . 1989;  25 405-408
• 35 Andrew M, Mitchell L, Vegh P, Ofosu F. Thrombin regulation in children differs from adults in the absence and presence of heparin.  Thromb Haemost . 1994;  72 836-842
• 36 Chan A K, Berry L R, Monagle P T, Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential.  Thromb Haemost . 2002;  87 606-613
• 37 Cvirn G, Gallistl S, Leschnik B, Muntean W. Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates.  J Thromb Haemost . 2003;  1 263-268
• 38 Knöfler R, Hofmann S, Weissbach G. et al . Molecular markers of the endothelium, the coagulation, and the fibrinolytic systems in healthy newborns.  Semin Thromb Hemost . 1998;  24 453-461
• 39 Ries M, Klinge J, Rauch R. Age-related reference values for activation markers of the coagulation and fibrinolytic systems in children.  Thromb Res . 1997;  85 341-344